RecruitingNCT06854081
EluPro Antibiotic-Eluting BioEnvelope Registry
A Multi-Center Registry Evaluating EluPro Antibiotic-Eluting BioEnvelope During CIED Implantation
Sponsor
Elutia Inc.
Enrollment
100 participants
Start Date
Apr 17, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
A Multi-Center Registry Study Evaluating Participants Who Receive EluPro Antibiotic-Eluting BioEnvelope During CIED Implantation
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Patient is undergoing implantation of EluPro with either a de novo CIED implantation or has an existing CIED and is undergoing CIED replacement or upgrade.
- Patient is willing to comply with scheduled follow-up and study-related visits.
- Patient is 18 years of age or older at the time of enrollment.
- Patient agrees to provide written informed consent and use of PHI.
Exclusion Criteria9
- Patient has a prior history of CIED infection, other prosthetic device infection, or endovascular infection, including endocarditis, in the past 12 months.
- Patient is exhibiting signs or symptoms consistent with any type of active infection (including but not limited to pneumonia, urinary tract, cellulitis, or bacteremia).
- Patient has Stage 4 or 5 kidney disease (eGFR <30 ml/min).
- Patient requires long-term vascular access for any reason.
- Patient is undergoing implantation of a CIED that does not fit completely into EluPro, preventing closure of the bioenvelope to secure the CIED.
- Patient is currently on chronic immunosuppressive agents or ≥20mg/day of Prednisone or equivalent.
- Patient has known allergy to minocycline or rifampin or their derivatives, or any other known contraindications to the implantation of EluPro.
- Patient is participating in another clinical study that could impact the outcome and documented pre-approval from the study sponsor has not been obtained.
- Female patient who is pregnant, or of childbearing potential and not on a reliable form of birth control. Women of childbearing potential are required to have a negative pregnancy test within 7 days prior to device procedure.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
COMBINATION_PRODUCTEluPro Antibiotic-Eluting BioEnvelope
Utilization of an EluPro Antibiotic-Eluting BioEnvelope with the CIED during the participant's CIED implant procedure.
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06854081
Related Trials
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
NCT057241211 location
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
NCT0589071614 locations
ViewFlex X ICE First-in-Human Study
NCT067724937 locations
Bad Berka Heart Rhythm Registry of Patients With or at Risk of Arrhythmias Treated at Heart Center Bad Berka
NCT070209101 location
Utility of Gene Test Analysis for Diagnosis, Prognosis and Treatment of Patients With Genetic Arrhythmic Heart Disease: the ARRHYTHMIC GENE-HEART
NCT068983071 location